PE20110424A1 - Isoindolonas que inhiben la cinasa mek - Google Patents
Isoindolonas que inhiben la cinasa mekInfo
- Publication number
- PE20110424A1 PE20110424A1 PE2010001200A PE2010001200A PE20110424A1 PE 20110424 A1 PE20110424 A1 PE 20110424A1 PE 2010001200 A PE2010001200 A PE 2010001200A PE 2010001200 A PE2010001200 A PE 2010001200A PE 20110424 A1 PE20110424 A1 PE 20110424A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- halo
- isoindolones
- mek kinase
- inhibit mek
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- CUMTUBVTKOYYOU-UHFFFAOYSA-N 2-fluoro-4-iodoaniline Chemical compound NC1=CC=C(I)C=C1F CUMTUBVTKOYYOU-UHFFFAOYSA-N 0.000 abstract 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 abstract 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
REFERIDA A DERIVADOS DE ISOINDOLONAS DE FORMULA (I), DONDE Z1 ES CR1R1a O NRA; R1 Y R1a SON H, ALQUILO C1-C3, CF3, CHF2, CN O ORA; Z2 ES CR2 O N; R2 ES H, ALQUILO C1-C3, HALO, CF3, ENTRE OTROS; Z3 ES CR3 O N; R3 ES H, HALO, CN, CF3, ENTRE OTROS; R4 ES H, ALQUILO C1-C6, CARBOCICLILO C3-C4; Y ES W-C(O)- O W'; W ES X1-NR5- O R11-O-; R5 ES H O ALQUILO C1-C12; X1 ES R11 O OR11; R11' ES H, ALQUILO C1-C12, ALQUINILO C2-C8, ENTRE OTROS; R11 ES H, ALQUILO C1-C12, ALQUENILO C2-C8, ENTRE OTROS; W' ES Het-R7, -NH-SO2-R8, -NH-SO2-NR8R10; Het ES (a), (b), ENTRE OTROS; X2 ES O, S, ENTRE OTROS; R7 ES H, HALO, CN, CF3, ENTRE OTROS; R8 ES ALQUILO C1-C12, ARILO, ENTRE OTROS; R10 ES H, ALQUILO C1-C6 O CARBOCICLILO C3-C4; R6 ES H, HALO, ALQUILO C1-C6, ALQUENILO C2-C8, ENTRE OTROS; p ES 0, 1, 2 O 3. ES UN COMPUESTO PREFERIDO: (2-HIDROXI-ETOXI)-AMIDA DEL ACIDO 6-(2-FLUORO-4-YODO-FENILAMINO)-1-OXO-2,3-DIHIDRO-1H-ISOINDOL-5-CARBOXILICO. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA CINASA MEK Y SON UTILES EN EL TRATAMIENTO DEL CANCER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7743208P | 2008-07-01 | 2008-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20110424A1 true PE20110424A1 (es) | 2011-07-22 |
Family
ID=41128054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2010001200A PE20110424A1 (es) | 2008-07-01 | 2009-07-01 | Isoindolonas que inhiben la cinasa mek |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8492427B2 (es) |
| EP (1) | EP2307364B1 (es) |
| JP (1) | JP5615274B2 (es) |
| KR (1) | KR20110028376A (es) |
| CN (1) | CN102137843A (es) |
| AU (1) | AU2009266953A1 (es) |
| BR (1) | BRPI0910200A2 (es) |
| CA (1) | CA2727252A1 (es) |
| CL (1) | CL2010001637A1 (es) |
| ES (1) | ES2426096T3 (es) |
| IL (1) | IL209892A0 (es) |
| MX (1) | MX2010014565A (es) |
| PE (1) | PE20110424A1 (es) |
| RU (1) | RU2495028C2 (es) |
| WO (1) | WO2010003022A1 (es) |
| ZA (1) | ZA201008962B (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2806734A1 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
| EP2598660B1 (en) | 2010-07-26 | 2017-03-15 | Biomatrica, INC. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
| CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
| AU2013337702A1 (en) | 2012-11-02 | 2015-05-21 | Merck Patent Gmbh | Method of reducing adverse effects in a cancer patient undergoing treatment with a MEK inhibitor |
| EP3249054A1 (en) | 2012-12-20 | 2017-11-29 | Biomatrica, INC. | Formulations and methods for stabilizing pcr reagents |
| CN105491883B (zh) | 2013-06-13 | 2018-11-02 | 生物马特里卡公司 | 细胞稳定化 |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| US9914703B2 (en) * | 2013-10-25 | 2018-03-13 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof |
| JP6466461B2 (ja) | 2014-02-03 | 2019-02-06 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | Ｒｏｒガンマのジヒドロピロロピリジン阻害剤 |
| CN103922992B (zh) * | 2014-04-25 | 2015-09-02 | 温州大学 | 一种抗癌活性吲哚酮衍生物、合成方法及其用途 |
| ES2891555T3 (es) | 2014-06-10 | 2022-01-28 | Biomatrica Inc | Estabilización de trombocitos a temperaturas ambiente |
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| AU2015333610B2 (en) | 2014-10-14 | 2019-11-07 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| CN104860869B (zh) * | 2015-04-03 | 2017-11-03 | 北京大学 | 具有mek激酶抑制功能的化合物及其制备方法与应用 |
| EA034776B1 (ru) | 2015-05-20 | 2020-03-19 | Эмджен Инк. | Триазоловые агонисты рецептора apj |
| ES2856931T3 (es) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | Moduladores de ROR-gamma |
| WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
| BR112018010018A2 (pt) | 2015-11-20 | 2018-11-21 | Vitae Pharmaceuticals Inc | moduladores de ror-gama |
| KR102589056B1 (ko) | 2015-12-08 | 2023-10-12 | 바이오매트리카 인코포레이티드 | 적혈구 침강 속도의 감소 |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| KR20180134347A (ko) | 2016-04-15 | 2018-12-18 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
| US9988369B2 (en) | 2016-05-03 | 2018-06-05 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the APJ receptor |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| WO2018093580A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
| EP3541805B1 (en) | 2016-11-16 | 2020-10-14 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
| US11020395B2 (en) | 2016-11-16 | 2021-06-01 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor |
| US11191762B2 (en) | 2016-11-16 | 2021-12-07 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the APJ Receptor |
| US11021486B2 (en) | 2017-06-23 | 2021-06-01 | Cstone Pharmaceuticals | Coumarin-like cyclic compound as MEK inhibitor and use thereof |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| MX2020000887A (es) | 2017-07-24 | 2020-07-22 | Vitae Pharmaceuticals Llc | Inhibidores de ror?. |
| JP7530829B2 (ja) | 2017-09-08 | 2024-08-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの診断及び治療方法 |
| US11149040B2 (en) | 2017-11-03 | 2021-10-19 | Amgen Inc. | Fused triazole agonists of the APJ receptor |
| EP3735404B1 (en) | 2018-01-02 | 2023-11-29 | Seal Rock Therapeutics, Inc. | Ask1 inhibitor compounds and uses thereof |
| US20210008047A1 (en) | 2018-02-13 | 2021-01-14 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| JP2024521788A (ja) | 2021-05-27 | 2024-06-04 | ミラティ セラピューティクス， インコーポレイテッド | 併用療法 |
| WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA920592A (en) | 1970-05-28 | 1973-02-06 | Denzel Theodor | Amino derivatives of pyrazolo-pyridine carboxylic acids and esters |
| US3736326A (en) | 1971-03-29 | 1973-05-29 | Squibb & Sons Inc | Isoxazolopyridine carboxylic acids and esters |
| US4012373A (en) | 1972-09-22 | 1977-03-15 | E. R. Squibb & Sons, Inc. | Pyrazolo[3',4'-2,3]pyrido[4,5-e]b-benzo-1,5-diazepinones |
| GB8404586D0 (en) | 1984-02-22 | 1984-03-28 | Beecham Group Plc | Compounds |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| WO2001005390A2 (en) | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
| JP2002020386A (ja) | 2000-07-07 | 2002-01-23 | Ono Pharmaceut Co Ltd | ピラゾロピリジン誘導体 |
| DZ3401A1 (fr) | 2000-07-19 | 2002-01-24 | Warner Lambert Co | Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques |
| PA8569301A1 (es) * | 2002-03-13 | 2004-10-08 | Array Biopharma Inc | "derivados de bencimidazol n3 alquilado como inhibidores de mek" "n3 alkylated benzimidazole derivatives as mek inhibitors" |
| KR20040098013A (ko) | 2002-03-13 | 2004-11-18 | 어레이 바이오파마 인크. | Ｍｅｋ 억제제로서의 ｎ3 알킬화된 벤즈이미다졸 유도체 |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| GB0316237D0 (en) | 2003-07-11 | 2003-08-13 | Astrazeneca Ab | Therapeutic agents |
| GB0316232D0 (en) | 2003-07-11 | 2003-08-13 | Astrazeneca Ab | Therapeutic agents |
| US20050049276A1 (en) | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| WO2005009975A2 (en) * | 2003-07-24 | 2005-02-03 | Warner-Lambert Company Llc | Benzimidazole derivatives as mek inhibitors |
| US20050113398A1 (en) | 2003-08-07 | 2005-05-26 | Ankush Argade | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
| US7538120B2 (en) * | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| BRPI0416692A (pt) | 2003-11-19 | 2007-01-30 | Array Biopharma Inc | inibidores heterocìclicos de mek e métodos de emprego destes |
| EP1697304B1 (en) | 2003-11-25 | 2008-02-20 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
| WO2005058858A1 (en) | 2003-12-19 | 2005-06-30 | Biovitrum Ab | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder |
| ES2338060T3 (es) | 2003-12-22 | 2010-05-03 | Basilea Pharmaceutica Ag | Componentes de tipo ariloxi y ariltoxia-cetofenona para el tratamiento del cancer. |
| EP1699488A2 (en) | 2003-12-23 | 2006-09-13 | Pfizer Products Incorporated | Therapeutic combination for cognition enhancement and psychotic disorders |
| CA2620864A1 (en) | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| CN103524392B (zh) | 2005-10-07 | 2018-06-01 | 埃克塞利希斯股份有限公司 | 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶 |
| BRPI0716224A2 (pt) | 2006-08-31 | 2013-10-15 | Array Biopharma Inc | Compostos inibidores de raf e métodos de uso dos mesmos. |
-
2009
- 2009-07-01 JP JP2011516857A patent/JP5615274B2/ja not_active Expired - Fee Related
- 2009-07-01 US US12/998,000 patent/US8492427B2/en not_active Expired - Fee Related
- 2009-07-01 ES ES09774472T patent/ES2426096T3/es active Active
- 2009-07-01 WO PCT/US2009/049449 patent/WO2010003022A1/en not_active Ceased
- 2009-07-01 EP EP09774472.6A patent/EP2307364B1/en active Active
- 2009-07-01 MX MX2010014565A patent/MX2010014565A/es active IP Right Grant
- 2009-07-01 KR KR1020117002455A patent/KR20110028376A/ko not_active Ceased
- 2009-07-01 CA CA2727252A patent/CA2727252A1/en not_active Abandoned
- 2009-07-01 CN CN2009801337804A patent/CN102137843A/zh active Pending
- 2009-07-01 AU AU2009266953A patent/AU2009266953A1/en not_active Abandoned
- 2009-07-01 BR BRPI0910200A patent/BRPI0910200A2/pt not_active IP Right Cessation
- 2009-07-01 RU RU2011103434/04A patent/RU2495028C2/ru not_active IP Right Cessation
- 2009-07-01 PE PE2010001200A patent/PE20110424A1/es not_active Application Discontinuation
-
2010
- 2010-12-09 IL IL209892A patent/IL209892A0/en unknown
- 2010-12-13 ZA ZA2010/08962A patent/ZA201008962B/en unknown
- 2010-12-30 CL CL2010001637A patent/CL2010001637A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011526924A (ja) | 2011-10-20 |
| IL209892A0 (en) | 2011-02-28 |
| US8492427B2 (en) | 2013-07-23 |
| WO2010003022A8 (en) | 2010-09-30 |
| RU2495028C2 (ru) | 2013-10-10 |
| MX2010014565A (es) | 2011-03-04 |
| ZA201008962B (en) | 2012-03-28 |
| AU2009266953A1 (en) | 2010-01-07 |
| BRPI0910200A2 (pt) | 2015-09-29 |
| RU2011103434A (ru) | 2012-08-10 |
| WO2010003022A1 (en) | 2010-01-07 |
| ES2426096T3 (es) | 2013-10-21 |
| CA2727252A1 (en) | 2010-01-07 |
| AU2009266953A2 (en) | 2011-01-27 |
| EP2307364A1 (en) | 2011-04-13 |
| JP5615274B2 (ja) | 2014-10-29 |
| CN102137843A (zh) | 2011-07-27 |
| US20110124622A1 (en) | 2011-05-26 |
| KR20110028376A (ko) | 2011-03-17 |
| CL2010001637A1 (es) | 2011-07-15 |
| EP2307364B1 (en) | 2013-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110424A1 (es) | Isoindolonas que inhiben la cinasa mek | |
| ES2528797T3 (es) | Compuestos de aza-benzotiofenilo y métodos de uso | |
| PE20081354A1 (es) | Compuestos de azaindolilo como inhibidores de mek | |
| PE20091158A1 (es) | 5-anilinoimidazopiridinas y metodos de uso | |
| PE20081630A1 (es) | Quinazolinas para la inhibicion de pdk1 | |
| PE20121048A1 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
| CL2012000311A1 (es) | Compuestos derivados que contiene ciclos con 3 atomos de nitrogeno; utiles en el tratamiento de parasitosis en animales. | |
| PE20081174A1 (es) | Inhibidores de metaloproteasas derivados de heterociclos | |
| PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
| EA200800182A1 (ru) | Циклические анилинопиридинотриазины в качестве ингибиторов gsk-3 | |
| PE20140609A1 (es) | Diazacarbazoles y metodos de uso | |
| PE20081353A1 (es) | Compuestos del inhibidor de fosfoinositida 3-cinasa | |
| CR20190423A (es) | Nuevos compuestos biciclícos como inhibidores dobles de atx/ca | |
| MA38540B1 (fr) | Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6 | |
| GEP201706728B (en) | Noxious organism control agent | |
| EA201100037A1 (ru) | Органические соединения | |
| PE20120690A1 (es) | Derivados de 5-fluoropirimidinona | |
| BR112014027143A2 (pt) | pirrolobenzodiazepinas | |
| TW200736363A (en) | Material for organic electroluminescent device and organic electroluminescent device | |
| PE20141120A1 (es) | Compuestos heterociclicos | |
| AR084011A1 (es) | Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| PE20141361A1 (es) | Compuesto heterociclico dihidroxi aromatico | |
| MY169179A (en) | Novel piperidine compound or salt thereof | |
| MX2016017405A (es) | Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen. | |
| MX2010007543A (es) | Inhibidores de iap. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |